Your browser doesn't support javascript.
loading
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
Huang, Yunda; Zhang, Lily; Eaton, Amanda; Mkhize, Nonhlanhla N; Carpp, Lindsay N; Rudnicki, Erika; DeCamp, Allan; Juraska, Michal; Randhawa, April; McDermott, Adrian; Ledgerwood, Julie; Andrew, Philip; Karuna, Shelly; Edupuganti, Srilatha; Mgodi, Nyaradzo; Cohen, Myron; Corey, Lawrence; Mascola, John; Gilbert, Peter B; Morris, Lynn; Montefiori, David C.
Affiliation
  • Huang Y; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Zhang L; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Eaton A; Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Mkhize NN; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Carpp LN; Duke Human Vaccine Institute, Department of Surgery, Duke University, Durham, North Carolina, USA.
  • Rudnicki E; National Institute for Communicable Diseases, Johannesburg, South Africa.
  • DeCamp A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Juraska M; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Randhawa A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • McDermott A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Ledgerwood J; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Andrew P; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Karuna S; Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Edupuganti S; Family Health International, Durham, North Carolina, USA.
  • Mgodi N; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Cohen M; Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, Georgia, USA.
  • Corey L; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
  • Mascola J; Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Gilbert PB; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Morris L; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Montefiori DC; Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Hum Vaccin Immunother ; 18(1): 1908030, 2022 12 31.
Article in En | MEDLINE | ID: mdl-34213402
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / HIV Seropositivity Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Hum Vaccin Immunother Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / HIV Seropositivity Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Hum Vaccin Immunother Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos